drugset
drugset / Trial / NCT01564329

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

NCT01564329 ↗

Phase 2 Unknown 20 enrolled Simcere Pharmaceutical Co., Ltd
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

To evaluate the change of blood perfusion before/after the use of Endostar, discuss the time sequence of Endostar TM in treating advanced lung adenocarcinoma in normalization window period.

Timeline

Start
2012-03
Primary completion
2013-04
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 7.5 mg/m2 Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

lung adenocarcinoma